Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Garenoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 5/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Garenoxacin SCHEMBL2902130 | 1.00 | KCNH2 (0.40) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL29711350 | 0.99 | KCNH2 (0.39) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL2898521 | 0.99 | KCNH2 (0.39) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL2898526 | 0.99 | KCNH2 (0.39) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL2901743 | 0.98 | KCNH2 (0.40) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL4995275 | 0.98 | KCNH2 (0.40) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL2103727 | 0.96 | KCNH2 (0.42) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL13575803 | 0.96 | KCNH2 (0.42) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL2897686 | 0.96 | KCNH2 (0.42) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Garenoxacin SCHEMBL29364878 | 0.96 | KCNH2 (0.42) | KCNH2KDM4EHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1031569-B1 | SALT OF A 7-ISOINDOLINEQUINOLONECARBOXYLIC ACID DERIVATIVE, MONOHYDRATE THEREOF AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO LTD (JP) | 2010-03-17 | — | — | EP | claimed |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | claimed |
| EP-1482789-A2 | PALATABLE ORAL SUSPENSION AND METHOD | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030187019-A1 | Palatable oral suspension and method | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | claimed |
| WO-2003077842-A2 | PALATABLE ORAL SUSPENSION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | claimed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | claimed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | claimed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | claimed |
| CN-102988280-B | Garenoxacin eye drops | UNIV XINXIANG MEDICAL | 2014-03-19 | — | — | CN | disclosed |
| CN-102988280-A | Garenoxacin eye drops | LI ZHENGMEI | 2013-03-27 | — | — | CN | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-6482835-B2 | SUCH AS (R)-1-CYCLOPROPYL-8-DIFLUOROMETHOXY-7-(1-METHYL-2,3-DIHYDRO-1H-5-ISOINDOLYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYL IC ACID METHANESULFONATE; CHEMICAL INTERMEDIATES; BACTERICIDES; CATALYSIS | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187019-A1 | Palatable oral suspension and method | TAS2R20, TAS2R60, TAS2R30 | KCNH2 880/4885KDM4E 782/4885HPGD 396/4885 |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | BRD7, IMPDH1, DDT | KCNH2 979/4885KDM4E 3440/4885HPGD 135/4885 |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | KCNQ2, CYP4X1, HAAO | KCNH2 52/4885KDM4E 601/4885HPGD 521/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | KCNH2 4861/4885KDM4E 4720/4885HPGD 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.